SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

KTOV RSS Feed
Add KTOV Price Alert      Hide Sticky   Hide Intro
Moderator: Sugarplum, ash111, BostonBull1990, TradeFlow, whan7
Search This Board:
Last Post: 9/27/2016 2:41:56 AM - Followers: 109 - Board type: Free - Posts Today: 2
\

 

US Office

1615 Suter’s Lane NW, Washington DC 20007, Tel:  +1-202-965-2215

Israel Office

One Azrieli Center, Round Tower, Tel Aviv 6701101



http://kitovpharma.com/

NQ : $KTOV





Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs
that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Kitov is developing combination drug products that treat the pain of osteoarthritis without causing cardiovascular problems.
These drugs will not only not need to be labeled with health warnings, but will actually be labeled as reducing the risk of
cardiovascular events. Kitov’s drugs have the potential to improve the health of millions of patients worldwide.
It is expected that physicians will prefer to prescribe them rather than prescribe two separate drugs, to improve their patients’ health and to reduce their own legal exposure.

Kitov is currently focusing two late-stage drugs. Both contain NSAIDs that are widely consumed throughout the world for treating osteoarthritis.
Each of Kitov’s drugs adds to the NSAID a second drug product that reduces hypertension.

KIT-301: Naproxen combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled
for 20-24 months from start of development.
KIT-302: Celecoxib combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled for 2015.

Osteoarthritis, affecting approximately half of all adults over the age of 50, is a degenerative disease of joints that can cause pain and limit mobility.
Exercise and weight control are important therapies for controlling symptoms, but for many patients medication is the next step in pain treatment.
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications for treating osteoarthritis pain.
However, these medications raise blood pressure (hypertension) and thereby increase the risk of heart attacks, strokes, and death.
This has led the US FDA to require including a black box warning in the labeling of all NSAIDs, warning of these increased cardiovascular risks.




 

Dr. John Paul Waymack – M.D., Sc.D.

Chairman of the Board of Directors and Chief Medical Officer

Dr. Waymack was one of the founders of Kitov Pharmaceuticals and has served as the Chairman of our Board of Directors and Chief Medical Officer since July 2013. Dr. Waymack has over 20 years of experience in the biopharma field. Dr. Waymack is a former academic transplant surgeon and a former FDA medical officer, with over fifteen years of experience in drug development as a consultant to major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle. During his 10 years of academic career, Dr. Waymack published over 100 scientific essays, mainly in the fields of prostaglandins and immunology. In addition, Dr. Waymack volunteered to the U.S. army, where he was commissioned and served as a Major in the Medical Corp. in the position of Chief of Surgical Research in the U.S. Army’s Institute for Surgical Research. Dr. Waymack was also an associate professor of surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey.






 

NEWS :

Dec. 17, 2015 :  Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302
http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-reports-additional-data-from-its-phase-iii-trial-on-the-beneficial-blood-pressure-effects-of-kit-302-300194664.html


November 20, 2015 : Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-holdings-announces-pricing-of-us-initial-public-offering-and-nasdaq-listing-552301701.html


October 21, 2015 : Kitov Pharma Announces Completion of Patient Recruitment for the Phase III Clinical Trial for KIT-302
http://www.prnewswire.com/news-releases/kitov-pharma-announces-completion-of-patient-recruitment-for-the-phase-iii-clinical-trial-for-kit-302-535035241.html








 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KTOV
Current Price
Volume:
Bid Ask Day's Range
SureTrader
KTOV News: Report of Foreign Issuer (6-k) 09/07/2016 01:01:04 PM
KTOV News: Report of Foreign Issuer (6-k) 09/06/2016 08:27:57 AM
KTOV News: Report of Foreign Issuer (6-k) 08/17/2016 09:12:40 AM
KTOV News: Kitov Pharmaceuticals Issues First Half 2016 Financial Reports 08/17/2016 08:59:00 AM
KTOV News: Report of Foreign Issuer (6-k) 08/10/2016 09:01:06 AM
PostSubject
#3838  Sticky Note KTOV a very professional report (link inside)-"patient population ash111 09/21/16 04:30:30 PM
#3788  Sticky Note KTOV September 13th DD: Market Cap,Cash,sales prediction,Highlights: ash111 09/14/16 12:58:46 PM
#3365  Sticky Note 8/17/2016- Expected upcoming significant milestones + shr structure/OS : Sugarplum 08/17/16 10:58:46 AM
#3893   You ever hear of something called patience?Its been tmeier 09/27/16 02:41:56 AM
#3892   2% of O/S in volume is much higher ash111 09/27/16 12:54:17 AM
#3891   Traded a % of its value roughly. It's Youlie 09/26/16 10:50:50 PM
#3888   Look at the chart. Entered the Ichimoku cloud, TradeFlow 09/26/16 06:18:35 PM
#3887   on this slow day would anyone mind going ylama3 09/26/16 05:42:26 PM
#3886   Was there a lot of volume when you scottsmith 09/26/16 04:37:39 PM
#3885   I am in already for 3.14. Doubletree 09/26/16 04:34:40 PM
#3884   How low do you want it before you scottsmith 09/26/16 04:26:05 PM
#3883   What you mean ash with large bids, 120000 Doubletree 09/26/16 04:08:10 PM
#3882   another solid day. large bids into close. ash111 09/26/16 03:57:10 PM
#3881   Pfizer getting ready to spend big $$. http://mobile.reuters.com/article/idUSK scottsmith 09/26/16 03:26:25 PM
#3880   a strong buy http://www.investing.com/equities/kitov-pharmaceuticals-holdings-technical ash111 09/26/16 12:56:30 PM
#3879   Word seems to really be getting out on salgovernale69 09/26/16 12:15:19 PM
#3878   Nice buys/accumulation at 3.30 level! BostonBull1990 09/26/16 12:06:01 PM
#3877   Liking the volume vs tradable shares ash111 09/26/16 11:20:51 AM
#3876   Good early morning volume on the warrants too BostonBull1990 09/26/16 11:19:01 AM
#3875   Solid 2 trading days on tase too. ash111 09/26/16 11:10:28 AM
#3873   I get so excited checking twitter and investmenthub BostonBull1990 09/26/16 10:22:31 AM
#3872   I like the added cinematic effect. Thanks TrumpsVP 09/24/16 11:38:24 AM
#3871   $KTOV Kitov Pharmaceuticals Holdings September 2016 Company Presentation DITRstocks 09/23/16 10:19:30 PM
#3870   Just got around to doing this. Our day TradeFlow 09/23/16 09:01:10 PM
#3869   Accumulation continues on both. ash111 09/23/16 03:43:42 PM
#3868   I couldn't agree with you more, Scott. TrumpsVP 09/22/16 11:31:26 PM
#3867   That really is one of the best finds TrumpsVP 09/22/16 11:28:38 PM
#3866   I like this for low risk as P3 Amatuer17 09/22/16 07:59:31 PM
#3865   This to me looks like a much better scottsmith 09/22/16 06:47:51 PM
#3864   Yeah, many of us have gone deep into RBNEWS 09/22/16 04:20:05 PM
#3863   Teva is an obvious potential acquirer. I'm salgovernale69 09/22/16 03:28:20 PM
#3862   http://www.nasdaq.com/symbol/ktov/institutional-holdings Sabby and the rest invested about $12m ash111 09/22/16 03:26:45 PM
#3861   Is there any ownership summary in table format $Moneypenny$ 09/22/16 03:19:38 PM
#3860   I wish.. float should be close to 50% ash111 09/22/16 12:10:14 PM
#3859   Looks good here Ash, you own 51% of highjaxx 09/22/16 12:05:14 PM
#3858   Agree. ash111 09/22/16 01:25:04 AM
#3857   Well said, Sal. It's no different than TrumpsVP 09/21/16 11:21:16 PM
#3856   Report looked great, I hope it brings the BostonBull1990 09/21/16 08:39:26 PM
#3855   I should clarify, all those other great stocks salgovernale69 09/21/16 08:32:09 PM
#3854   Make no mistake KTOV paid for the report, salgovernale69 09/21/16 08:30:35 PM
#3853   Not at all actually, I just finished all BostonBull1990 09/21/16 08:10:38 PM
#3852   Amen! If you read the report, did you detect scottsmith 09/21/16 08:02:40 PM
#3851   I could be completely wrong, and I hope BostonBull1990 09/21/16 08:01:29 PM
#3850   I'm a little skeptical of LifeSci initiating coverage, BostonBull1990 09/21/16 07:59:23 PM
#3849   Pfizer. They renewed there patent for Celebrex last $Moneypenny$ 09/21/16 06:24:51 PM
#3848   Agree Ash. Talking the whole world here. RBNEWS 09/21/16 06:16:47 PM
#3847   Could we make the LifeSci a sticky. It's $Moneypenny$ 09/21/16 05:53:08 PM
#3846   I will take also a modest BO of ash111 09/21/16 05:25:46 PM
#3845   I'm going with KTOV being worth $100/ share Backdraft4u 09/21/16 05:19:50 PM
#3844   Don't be surprised ktov worth $60 per share LearnToTrade 09/21/16 05:06:30 PM
#3843   our mega day will come. ash111 09/21/16 04:52:50 PM
#3842   market potential will be much higher-"patient population for ash111 09/21/16 04:43:44 PM
#3841   Yea man. Any way you slice it scottsmith 09/21/16 04:43:37 PM
PostSubject